Effect of Ocriplasmin in the treatment of vitreomacular adhesion

Ocriplasmin (Ocriplasmin) is a recombinant protease drug developed to treat symptomatic vitreomacular adhesion (VMA). This disease mainly occurs in middle-aged and elderly people. As the vitreous body liquefies and the retina is not completely separated, it causes the macular area to be stretched, resulting in visual distortion, central vision loss, and even macular holes. Oakplasmin has become a major breakthrough in the field of ophthalmology treatment through a non-surgical drug dissolving mechanism.

Ocriplasmin works based on its ability to break down structural proteins at the junction of the vitreous and the retina, especially fibronectin and laminin. By injecting this enzyme preparation, the vitreous body can be naturally detached from the macular area, thereby alleviating mechanical traction and restoring the physiological state of the macula. Compared with traditional vitrectomy, the advantage of Oakplasmin is that it does not require surgical intervention and can be treated with a single intravitreal injection under local anesthesia.

Multiple studies have shown that Oakplasmin can completely relieve macular traction in some patients, and the recovery speed is faster. Some patients experience significant improvement in central vision within a few weeks. More importantly, the drug offers a new option for patients who are not candidates for or at risk for surgery. Although not all patients can achieve complete separation, the safety profile of Ocriplasmin is generally good. Common adverse reactions include temporary blurred vision, eye pain or floater sensation, which usually resolve spontaneously in the short term.

Generally speaking, in clinical application, doctors will decide whether to use Oak plasmin based on the severity of vitreomacular adhesion, whether it is accompanied by macular holes, and the patient's visual function. This drug marks the official realization of the concept of "biochemical vitrectomy".

Reference materials:https://www.drugs.com/cdi/ocriplasmin.html